glp 1 manufacturing The GLP-1 weight loss revolution | Feature GLP‑1 Manufacturing Containment Solutions |

Patients who stop GLP-1 therapy often regain weight within months, but steady access removes the financial friction that causes treatment gaps

While the current MDL in the Eastern District of Pennsylvania centers on gastrointestinal injuries, the growing number of NAION-related claims has raised the question of whether the MDL may eventually expand to include additional categories of injury

Even when it presents with unilateral vision loss, the contralateral eye becomes affected within 3 years in approximately 45% 50% of patients

This central adiposity carries greater health implications, including elevated risks for cardiovascular disease and type 2 diabetes

The current state of access to weight loss drugs isnt serving everyone who needs them, said Andrew Dudum, CEO and co-founder of Hims & Hers